The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| STRO | -67.14% | -90.57% | -37.64% | -92% |
| S&P | +14.5% | +93.32% | +14.09% | +130% |
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Phase 1 data for its ovarian cancer candidate was a little disappointing.
One of the company's pipeline treatments shows encouraging results in ovarian cancer patients.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $63.75M | 148.0% |
| Gross Profit | $61.85M | 158.6% |
| Gross Margin | 97.02% | 4.0% |
| Market Cap | $60.30M | -74.8% |
| Market Cap / Employee | $0.25M | 0.0% |
| Employees | 244 | 0.0% |
| Net Income | -$11.50M | 76.1% |
| EBITDA | $16.98M | 136.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $64.03M | -29.5% |
| Accounts Receivable | $8.00M | 15.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $211.62M | 15.3% |
| Short Term Debt | $8.06M | 16.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.55% | -29.5% |
| Return On Invested Capital | -43.88% | -8.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$44.81M | -615.1% |
| Operating Free Cash Flow | -$44.72M | -573.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.86 | 1.36 | 1.20 | -2.33 | -224.97% |
| Price to Sales | 1.76 | 2.45 | 0.81 | 0.58 | -58.87% |
| Price to Tangible Book Value | 1.86 | 1.36 | 1.20 | -2.33 | -224.97% |
| Enterprise Value to EBITDA | -1.40 | -0.61 | -0.37 | 4.41 | -8626.84% |
| Return on Equity | -110.9% | -234.2% | -679.1% | -347.6% | 328.64% |
| Total Debt | $196.83M | $203.96M | $211.70M | $219.68M | 15.36% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
